Cantor Fitzgerald, L. P. Aptevo Therapeutics Inc. Transaction History

Cantor Fitzgerald, L. P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.17 - $0.38 $32,740 - $73,184	-192,590 Reduced 76.69%	58,532 $10,000
Q2 2023 Aug 14, 2023	BUY	$1.34 - $2.08 $43,445 - $67,437	32,422 Added 14.82%	251,122 $366,000
Q1 2023 May 15, 2023	BUY	$1.74 - $2.54 $6,090 - $8,890	3,500 Added 1.63%	218,700 $446,000
Q4 2022 Feb 14, 2023	BUY	$2.0 - $138.16 $163,000 - $11.3 Million	81,500 Added 60.96%	215,200 $499,000
Q3 2022 Nov 14, 2022	BUY	$3.12 - $142.56 $417,144 - $19.1 Million	133,700 New	133,700 $406,000

Ticker APVO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,090,640
Market Cap $24.5M
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...

Get notified when there are updates to the investment portfolio of Cantor Fitzgerald, L. P., based on Form 13F filings with the SEC.

Stay updated on Cantor Fitzgerald, L. P. with notifications on news.